Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
about
Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolveNovel delivery strategies for glioblastomaTumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapyTargeting autophagy to sensitive glioma to temozolomide treatmentLinking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling.Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cellsDasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinibAutophagy in the placenta.Mesenchymal migration as a therapeutic target in glioblastoma.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Experimental approaches for the treatment of malignant gliomas.Dasatinib induces autophagic cell death in human ovarian cancer.Small-molecule regulators of autophagy and their potential therapeutic applications.Lyn facilitates glioblastoma cell survival under conditions of nutrient deprivation by promoting autophagy.Pathway inhibition: emerging molecular targets for treating glioblastoma.Src family kinases and paclitaxel sensitivity.Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studiesThe pan erbB inhibitor PD168393 enhances lysosomal dysfunction-induced apoptotic death in malignant peripheral nerve sheath tumor cellsAutophagy activation: a novel mechanism of atorvastatin to protect mesenchymal stem cells from hypoxia and serum deprivation via AMP-activated protein kinase/mammalian target of rapamycin pathwayUnfolded protein response to autophagy as a promising druggable target for anticancer therapy.Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model.Autophagy is required for IL-2-mediated fibroblast growth.Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant gliomaTherapeutic targeting of autophagy in disease: biology and pharmacology.NO-mediated activation of Src kinase during hypoxia in the cerebral cortex of newborn pigletsImproving the prognosis for patients with glioblastoma: the rationale for targeting Src.Genomic analyses reveal broad impact of miR-137 on genes associated with malignant transformation and neuronal differentiation in glioblastoma cells.Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells.Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?Modulating autophagy: a strategy for cancer therapyAntiangiogenic therapies in glioblastoma multiforme.Therapeutic targets in cancer cell metabolism and autophagy.Autophagic action of new targeting agents in head and neck oncology.Autophagy as a target for cancer therapy: new developmentsInterferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy.Autophagy, a double-edged sword in anti-angiogenesis therapy.SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment.
P2860
Q26764947-C4DC0B77-8B1B-48AE-B714-76C2A06BF28BQ27006099-6E3F0C1A-AC72-4786-8C52-CAECD985B660Q27024127-5D860880-D872-4CF1-B8A2-24DF0BA3A9D0Q28066270-3E56D9DC-CB9C-44E6-A0F3-3B7BD3FEC949Q30588679-826FEA98-C7AA-42C1-B012-AB38198E873FQ33574951-D4C76456-6FCB-452D-9F07-710B4CFED8E0Q33577628-AF3FAC41-530A-4D71-A672-204B8BD2AC15Q33655352-DEE08A5E-0388-4A63-AA48-C65CDE1B6929Q33711844-4696491B-B54D-44D3-9C03-833EA22E1CCCQ34002994-DEA5AB56-0796-4AF5-9BBB-068D5C110DFCQ34121339-1913811A-0694-4C3C-AA4A-1AA74A607134Q34127138-FE8729D5-192D-4E83-BDBE-CDA12A595842Q34286944-33740D33-86E8-4914-AF2A-6265F0D9C698Q34660074-5361EBE7-006E-45F9-941A-86920DA2DE02Q34926222-13E54D1F-F6C8-4F28-BF11-0D9410F88A9FQ35021359-F391D713-CDC8-4097-BD4B-E82D0C2D4C43Q35214722-03F9B19B-85B1-42A8-AECF-F4F64DC34B82Q35539318-792F13C5-A04B-4D4A-AE06-2813C7837D4DQ35760676-7AE1A878-DEB9-4A99-B134-884E84BB668CQ35964826-2B3E0F8F-7E36-4391-836C-73B253B1C6E9Q36403652-EB4E7B05-1ECC-4E9E-9154-1BE1793C37DEQ36520705-4B8789D5-EC88-443C-87E7-BFF281831345Q36585665-A2BEF8B9-D390-45DF-A2AE-E79A33340060Q36949546-67275894-7AA5-475C-9579-D6453BA2E241Q37236107-2B11B30F-E05C-4576-B9A5-248C6C040DF2Q37241906-7F955982-F18C-431D-8F0C-C06D734CD5B0Q37479213-0AC0F06B-78EA-43ED-9D44-97856CD930F4Q37505070-4FFA86DD-CC84-414A-8897-F66F485FF51AQ37613072-9C2042FE-53CC-42AB-A762-71201AC1637CQ37688839-ACF155A3-FCCE-4411-AA87-9FE2334017F0Q37736273-B0995C85-C22F-4E5E-B4DC-ADCBBFD20D18Q37799220-FB938653-2884-4561-AD43-0DC120FB0549Q37940741-EA72CCF5-D99F-4BEE-AD59-ACA23058AC83Q38010802-E9895AA9-E91F-4FDA-BA04-75F1FA10B582Q38025264-080ED0B3-4814-4830-8672-E2FCAADF1853Q38028794-94644315-9525-41A5-B647-E37E1C465F8DQ38054710-1CACF486-60B5-404A-9906-CD71058D58C8Q38260673-3B97C805-54B3-4EA5-8D9F-22020B962B51Q38682453-EC307A93-349F-4071-8E48-F154CAA19934Q38927421-C64EF850-7340-4C2F-8729-E4688997A36D
P2860
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
@en
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
@nl
type
label
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
@en
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
@nl
prefLabel
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
@en
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
@nl
P2093
P1476
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
@en
P2093
John de Groot
Tiffany LaFortune
Vanessa Milano
P304
P356
10.1158/1535-7163.MCT-08-0669
P577
2009-02-03T00:00:00Z